

ASX Release

CHANGE OF NAME TO SUDA PHARMACEUTICALS LTD

PERTH, AUSTRALIA – 29 November 2017: At the recent AGM, shareholders passed the resolution to change the name from “Suda Ltd” to “Suda Pharmaceuticals Ltd”. The Company has now received formal notice of the change of name from ASIC. The ASX code will remain **SUD**.

The Board has considered feedback from investors and potential partners that the name “Suda Ltd” did not reflect the business operations and believed that by adding “Pharmaceuticals” to the name would provide a clearer message about the activities of the Company.

The new website address will be: www.sudapharma.com

The new logo is as above.

The Company anticipates that the new name will be changed on ASX from 5 December 2017.



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA Pharmaceuticals Ltd
Tel: +61 8 6142 5555
sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com